{
	"slug": "cdiff",
	"title": "Clostridium Difficile Infection",
	"authors": [
		"Michelle Lin, MD"
	],
	"created": "2011/06/24",
	"updates": null,
	"categories": [
		"Infectious Disease"
	],
	"body": "\n\n\n## Treatment\n\n| Clinical Category                   | Presentation                                 | Treatment                                                                                                                                             |\n| ----------------------------------- | -------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------- |\n| 1st episode, mild-moderate severity |                                              | <span class=\"drug\">Metronidazole</span> 500 mg PO TID x 10-14 days                                                                                    |\n| 1st episode, severe                 | Serum WBC ≥15k or creatinine > 1.5x baseline | <span class=\"drug\">Vancomycin</span> 125 mg PO QID x 10-14 days                                                                                       |\n| 1st episode, severe,complicated     | Hypotension, shock ileus, or megacolon       | <span class=\"drug\">Vancomycin</span> 500 mg QID PO/NG (PR if ileus) PLUS <span class=\"drug\">Metronidazole</span> 500 mg IV q8h</span>                 |\n| First recurrence                    |                                              | Same as for 1st episode (because minimal resistance)                                                                                                  |\n| Second and more recurrences         |                                              | <span class=\"drug\">Vancomycin</span> PO in tapered or pulsed regimen. Avoid <span class=\"drug\">metronidazole</span> overuse because of neurotoxicity. |\n\n## Background\n\n### Definition of _Clostridium difficile_ infection (CDI)\n\n- Presence of diarrhea (3 unformed stools in ≤24 hours)\n- Stool test positive for _C. difficile_ or its toxins, or colonoscopic findings of pseudomembranous colitis\n\n### Epidemiology\n\n- Accounts for 20-30% of all antibiotic-associated diarrhea\n- Most common cause of infectious diarrhea in healthcare settings\n\n### Transmission\n\n- Fecal-oral route\n- Median time from exposure to C. difficile to diarrhea symptoms = 2-3 days\n\n### Risk factors to develop CDI\n\n- Age &ge; 65 years\n- Duration of hospitalization\n- Exposure to antibiotics (almost every Abx has been assoc with CDI – not just <span class=\"drug\">clindamycin</span>)\n  - 96% have received abx within 14 days before diarrhea onset \n- Cancer chemotherapy\n- HIV\n- GI surgery or manipulation of GI tract (i.e. tube feeding)\n\n### Clinical presentation\n\n- Diarrhea may have mucous or occult blood\n\n### Recurrence rates\n\n- 20% (typically within 4 weeks), despite <span class=\"drug\">metronidazole</span> or <span class=\"drug\">vancomycin</span> treatment ([Kelly et al., NEJM, 2008](https://www.ncbi.nlm.nih.gov/pubmed/?term=18971494))\n\n## Complications\n\n- Bowel perforation\n- Dehydration\n- Electrolyte imbalance \n- Hypoalbuminemia\n- Hypotension\n- Renal failure\n- SIRS, sepsis\n- Toxic megacolon\n- Death\n\n## References\n\n- Cohen SH, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by SHEA and IDSA. Infect Control Hosp Epidemiol. 2010; 31(5):431-55. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=20307191)]\n- Kelly CP, LaMont JT.Clostridium difficile--more difficult than ever.N Engl J Med. 2008 Oct 30;359(18):1932-40. doi: 10.1056/NEJMra0707500. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=18971494)]\n"
}